Investor Relations
News Archive
Documents, filings, and announcements related to Healthcare Capital Corp. and the Alpha Tau Medical business combination.
Documents and Filings
- 01 8-K Filing 2/15/22
- 02 SEC Form Type 425 — 1/20/22
- 03 SEC Form Type 425 — Alpha Tau Medical Company Overview
- 04 SEC Form Type 425 Exhibit — Link to Press Release
- 05 8-K Filing 1/19/22
- 06 Business Combination Proxy Statement / Prospectus
- 07 Amendment No. 4 to Form F-4 — 1/10/22
- 08 SEC Form Type 425 — 1/10/22
- 09 SEC Form Type 425 — 1/3/22
- 10 Amendment No. 2 to Form F-4
- 11 8-K Filing 11/15/21
- 12 Form 10-Q
- 13 SEC Form Type 425 — 11/3/21
- 14 SEC Form Type 425 — 10/25/21
- 15 Amendment No. 1 to Form F-4 — 10/18/21
- 16 SEC Form Type 425 — 10/13/21
- 17 F-4 Registration Statement
- 18 8-K Filing
- 19 Alpha As-Filed F-4
News and Updates
- 01 Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
- 02 Healthcare Capital Corp. and Alpha Tau Medical Ltd. Announce Stockholder Approval of the Business Combination
- 03 Healthcare Capital Corp. Announces Adjournment of Special Meeting of Stockholders
- 04 Selected Questions and Answers About Stockholder Meeting of Healthcare Capital Corp. to Approve Its Business Combination with Alpha Tau Medical LTD.
- 05 Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
- 06 Healthcare Capital Corp Announces Special Meeting Date for Proposed Business Combination with Alpha Tau Medical Ltd.
- 07 Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events
- 08 Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
- 09 Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
- 10 Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Primary Objective
- 11 Alpha Tau Receives FDA Breakthrough Device Designation for treatment of Recurrent Glioblastoma Multiforme (GBM)
- 12 Healthcare Capital Corp announces merger with Alpha Tau Medical